# A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Source: https://onco.cc/trials/nct05888493/  
OnCo record `nct05888493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tisagenlecleucel, Lenalidomide, Rituximab in follicular lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma is a phase 3 interventional study registered as NCT05888493 by Novartis Pharmaceuticals, with 109 participants enrolled, started 2023-10-02 and due to reach its primary completion in 2028-07-25. Interventions recorded: Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy). Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05888493
- Phase: 3
- Setting: A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 109

## Sources

- ClinicalTrials.gov NCT05888493: https://clinicaltrials.gov/study/NCT05888493

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/), [Vincristine](https://onco.cc/drugs/vincristine/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct05888493.json